60 Degrees Pharmaceuticals, Inc. has announced an increase in the maximum aggregate gross sales price of shares available under its At the Market Issuance Sales Agreement with WallachBeth Capital LLC to $2,295,192. This update, filed on August 2, 2024, amends previous prospectus supplements and the base prospectus, reflecting the increased offering size from the initial registration of $1,253,603. As of the filing date, the company has sold 8,133,821 shares for a total of $1,994,583.43. The common stock is traded on The Nasdaq Capital Market under the symbol 'SXTP.' The company's outstanding common stock held by non-affiliates is valued at approximately $6,885,578, based on the closing sale price on June 10, 2024. 60 Degrees Pharmaceuticals emphasizes that investing in its common stock carries significant risks, as detailed in the 'Risk Factors' section of the prospectus supplements and documents filed with the SEC.

60 Degrees Pharmaceuticals, Inc. has announced an increase in the maximum aggregate gross sales price of shares available under its At the Market Issuance Sales Agreement with WallachBeth Capital LLC to $2,295,192. This update, filed on August 2, 2024, amends previous prospectus supplements and the base prospectus, reflecting the increased offering size from the initial registration of $1,253,603. As of the filing date, the company has sold 8,133,821 shares for a total of $1,994,583.43. The common stock is traded on The Nasdaq Capital Market under the symbol 'SXTP.' The company's outstanding common stock held by non-affiliates is valued at approximately $6,885,578, based on the closing sale price on June 10, 2024. 60 Degrees Pharmaceuticals emphasizes that investing in its common stock carries significant risks, as detailed in the 'Risk Factors' section of the prospectus supplements and documents filed with the SEC.